EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis

Martin O Evans iD, Darren M Smith iD, Adrian T Kress, Robert J Nadeau, Daniel J Selig, Diana Caridha, Ratanachat Racharaks, Thomas Langowski, Michael S Madejczyk iD, Chance Carbaugh iD, David Saunders, Mark Widder und 3 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Martin O Evans und 14 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Cyclams, Zebrafish, Benzylamines, Sepsis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plerixafor is a CXCR4 antagonist approved in 2008 by the FDA for hematopoietic stem cell collection. Subsequently, plerixafor has shown promise as a potential pathogen‐agnostic immunomodulator in a variety of preclinical animal models. Additionally, investigator‐led studies demonstrated plerixafor prevents viral and bacterial infections in patients with WHIM syndrome, a rare immunodeficiency with aberrant CXCR4 signaling. Here, we investigated whether plerixafor could be repurposed to treat sepsis or severe wound infections, either alone or as an adjunct therapy. In a Pseudomonas aeruginosa lipopolysaccharide (LPS)‐induced zebrafish sepsis model, plerixafor reduced sepsis mortality and morbidity assessed by tail edema. There was a U‐shaped response curve with the greatest effect seen at 0.1 μM concentration. We used Acinetobacter baumannii infection in a neutropenic murine thigh infection model. Plerixafor did not show reduced bacterial growth at 24 h in the mouse thigh model, nor did it amplify the effects of a rifampin antibiotic therapy, in varying regimens. While plerixafor did not mitigate or treat bacterial wound infections in mice, it did reduce sepsis mortality in zebra fish. The observed mortality reduction in our LPS model of zebrafish was consistent with prior research demonstrating a mortality benefit in a murine model of sepsis. However, based on our results, plerixafor is unlikely to be successful as an adjunct therapy for wound infections. Further research is needed to better define the scope of plerixafor as a pathogen‐agnostic therapy. Future directions may include the use of longer acting CXCR4 antagonists, biased CXCR4 signaling, and optimization of animal models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclamsZebrafishBenzylaminesSepsisHeterocyclic CompoundsDisease Models, AnimalReceptors, CXCR4AnimalsMiceThighAcinetobacter InfectionsPseudomonas aeruginosaPseudomonas InfectionsFemaleLipopolysaccharidesWound InfectionAnti-Bacterial Agents

Substanzen

CyclamsplerixaforBenzylaminesHeterocyclic CompoundsReceptors, CXCR4LipopolysaccharidesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Experimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Uniformed Services University School of Medicine, Bethesda, Maryland, USA.

ORCID-Profile: Martin O Evans, Darren M Smith, Michael S Madejczyk, Chance Carbaugh

Zitieren

APA

Evans, M. O., Smith, D. M., Kress, A. T., Nadeau, R. J., Selig, D. J., Caridha, D., Racharaks, R., Langowski, T., Madejczyk, M. S., Carbaugh, C., Saunders, D., Widder, M., De Meese, J., Lee, P. J., & DeLuca, J. P. (2024). Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis. Clinical and Translational Science. https://doi.org/10.1111/cts.13876

Vancouver

Evans MO, Smith DM, Kress AT, Nadeau RJ, Selig DJ, Caridha D, et al. Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis. Clinical and Translational Science. 2024. doi:10.1111/cts.13876

BibTeX
@article{Evans2024,
  author = {Evans, Martin O and Smith, Darren M and Kress, Adrian T and Nadeau, Robert J and Selig, Daniel J and Caridha, Diana and Racharaks, Ratanachat and Langowski, Thomas and Madejczyk, Michael S and Carbaugh, Chance and Saunders, David and Widder, Mark and De Meese, Jason and Lee, Patricia J and DeLuca, Jesse P},
  title = {Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13876}
}
Kostenlos starten →